EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors

Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi-Sakita, Takanori Ishida, Takahiro Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai und 5 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02589-x ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Yoichi Naito und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. ynaito@east.ncc.go…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Camptothecin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sacituzumab govitecan (SG) is a Trop-2–directed antibody–drug conjugate approved outside Japan for second-line and later metastatic triple-negative breast cancer (mTNBC), based on the ASCENT study (NCT02574455). We report SG safety and efficacy in an open-label, phase 1/2 bridging study in Japanese patients with advanced solid tumors (ASCENT-J02; NCT05101096; jRCT2031210346).

Methods

Phase 1 was a standard 3 + 3 design. Patients received intravenous SG 6 mg/kg, escalating to 10 mg/kg, on Days 1 and 8 per 21-day cycle; primary endpoints were safety, incidence of dose-limiting toxicity/toxicities (DLTs), and determination of the recommended phase 2 dose (RP2D). In the multicohort phase 2 study, patients in the mTNBC cohort with previously treated disease received SG at the RP2D; primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR; RECIST v1.1). Safety was a secondary endpoint.

Results

In phase 1 ( N = 15), one DLT (grade 3 elevated transaminases) occurred with SG 10 mg/kg; RP2D was SG 10 mg/kg regardless of UGT1A1 status. In phase 2, 36 patients with mTNBC received SG 10 mg/kg. At median follow-up of 6.1 months, IRC-assessed ORR was 25.0% (95% CI 12.1–42.2; P = 0.0077). Median progression-free survival was 5.6 months (95% CI 3.9–not reached [NR]); median overall survival was NR. No treatment-emergent adverse events led to discontinuation or death.

Conclusions

SG RP2D was established as 10 mg/kg in Japanese patients. SG showed efficacy in Japanese patients with previously treated mTNBC, a manageable safety profile, and no new safety signals, consistent with the previous ASCENT study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCamptothecinHumansFemaleMiddle AgedAgedMaleAdultImmunoconjugatesJapanNeoplasmsProgression-Free SurvivalMaximum Tolerated DoseAged, 80 and overTriple Negative Breast NeoplasmsEast Asian People

Stichwörter der Autor:innen

Antibody–drug conjugateJapanese patientsMetastatic triple-negative breast cancerPhase 2Sacituzumab govitecan

Substanzen

Antibodies, Monoclonal, Humanizedsacituzumab govitecanCamptothecinImmunoconjugates

Autor:innen und Institutionen

  • Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. ynaito@east.ncc.go.jp.
  • Showa University Hospital, Tokyo, Japan.
  • Kyoto University Hospital, Kyoto, Japan.
  • Tohoku University Hospital, Miyagi, Japan.
  • Osaka International Cancer Institute, Osaka, Japan.
  • Kumamoto University Hospital, Kumamoto, Japan.

Förderung

  • Gilead Sciences

Zitieren

APA

Naito, Y., Nakamura, S., Kawaguchi-Sakita, N., Ishida, T., Nakayama, T., Yamamoto, Y., Masuda, N., Matsumoto, K., Kogawa, T., Sudo, K., Shimomura, A., Lai, C., Zhang, D., Iwahori, Y., Gary, D., Huynh, D., & Iwata, H. (2024). Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02589-x

Vancouver

Naito Y, Nakamura S, Kawaguchi-Sakita N, Ishida T, Nakayama T, Yamamoto Y, et al. Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02589-x

BibTeX
@article{Naito2024,
  author = {Naito, Yoichi and Nakamura, Seigo and Kawaguchi-Sakita, Nobuko and Ishida, Takanori and Nakayama, Takahiro and Yamamoto, Yutaka and Masuda, Norikazu and Matsumoto, Koji and Kogawa, Takahiro and Sudo, Kazuki and Shimomura, Akihiko and Lai, Catherine and Zhang, Danjie and Iwahori, Yuki and Gary, Dianna and Huynh, Danh and Iwata, Hiroji},
  title = {Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02589-x}
}
Kostenlos starten →